Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

rEV-131 for postcataract surgery impresses in preclinical study

Dec. 20, 2004

No Comments

Zylet receives FDA approval

Dec. 17, 2004

No Comments

Retisert NDA accepted for review

Dec. 17, 2004

No Comments

Single-use vial of Vitrase approved for use as spreading agent

Dec. 9, 2004

No Comments

GenVec licenses PEDF rights for ocular diseases

Dec. 2, 2004

No Comments

Putative melatonin receptor agonist promising for treatment of glaucoma

Nov. 30, 2004

No Comments

Sirna-027 enters phase I study for wet AMD

Nov. 25, 2004

No Comments

Merck claims prostaglandin analogues as EP4 receptor agonists for ocular and bone conditions

Nov. 24, 2004

No Comments

CA4P enters phase II study

Nov. 23, 2004

No Comments

ISTA licenses U.S. rights for ecabet sodium for dry eye

Nov. 22, 2004

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Ocular
RSS

rEV-131 for postcataract surgery impresses in preclinical study

Zylet receives FDA approval

Retisert NDA accepted for review

Single-use vial of Vitrase approved for use as spreading agent

GenVec licenses PEDF rights for ocular diseases

Putative melatonin receptor agonist promising for treatment of glaucoma

Sirna-027 enters phase I study for wet AMD

Merck claims prostaglandin analogues as EP4 receptor agonists for ocular and bone conditions

CA4P enters phase II study

ISTA licenses U.S. rights for ecabet sodium for dry eye

Today's news in brief

Today's news in brief

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space

GLP-1 receptor agonists continue their global victory tour

AI drives financings, approvals for APAC med-tech in 2024

Ocular RSS

Ocular
RSS